PK Study in Patients With Parkinson's Disease With IZD174

Parkinson Disease Clinical Trial

Official title: An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease

Status Withdrawn

Clinical Trial Summary

Single center, open-label, intra-individual dose-escalation study in subjects with mild/moderate Parkinson's Disease

Clinical Trial Description

After assessing eligibility during a screening period of up to 4 weeks, up to 6 subjects will be included.

Subjects will check into the clinic one day prior to dosing (Day -1). To evaluate and compare drug exposure levels in plasma and CSF, plasma and CSF will be serially sampled over a period of 36 hours. Subjects will be discharged from the clinic on Day 5 after all required study procedures are completed and if medically justified.

Subjects will return to the clinic approximately 1 week after discharge from the clinic for a follow-up visit. ;

Related Conditions & MeSH terms

• Parkinson Disease

• NCT number: NCT04338997
• Study type: Interventional
• Source: Inflazome UK Ltd
• Status: Withdrawn
• Phase: Phase 1
• Start date: October 2020
• Completion date: December 2020